LeMaitre Vascular, Inc. $LMAT Shares Sold by AWM Investment Company Inc.

AWM Investment Company Inc. lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 10.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 130,000 shares of the medical instruments supplier’s stock after selling 15,000 shares during the quarter. AWM Investment Company Inc. owned about 0.57% of LeMaitre Vascular worth $10,796,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Geneva Capital Management LLC lifted its holdings in LeMaitre Vascular by 6.0% in the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after acquiring an additional 51,489 shares during the period. Congress Asset Management Co. grew its position in LeMaitre Vascular by 4.6% during the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after buying an additional 29,553 shares during the period. First Trust Advisors LP increased its holdings in LeMaitre Vascular by 52.7% in the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after buying an additional 211,280 shares in the last quarter. Geode Capital Management LLC increased its holdings in LeMaitre Vascular by 3.0% in the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier’s stock valued at $43,174,000 after buying an additional 15,036 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of LeMaitre Vascular by 5.4% in the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock worth $28,993,000 after acquiring an additional 17,748 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $84.00 on Friday. The company has a market cap of $1.91 billion, a P/E ratio of 36.21, a P/E/G ratio of 2.06 and a beta of 0.68. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $105.55. The company’s 50-day moving average price is $86.53 and its 200-day moving average price is $87.12. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.05. The company had revenue of $61.05 million during the quarter, compared to the consensus estimate of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. LeMaitre Vascular’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s payout ratio is 34.48%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent analyst reports. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Wells Fargo & Company dropped their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Weiss Ratings restated a “hold (c+)” rating on shares of LeMaitre Vascular in a research report on Monday. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Finally, Roth Capital reissued a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average price target of $100.20.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.